A B S T R A C T Low density lipoprotein (LDL) catabolism occurs by LDL receptor-dependent and LDL receptor-independent pathways. We have shown previously that nonenzymatic glucosylation of LDL in the presence of cyanoborohydride irreversibly blocks the lysine residues of LDL. Glucosylated LDL (GLC-LDL) was not degraded by the LDL receptor of fibroblasts, and its degradation by macrophages was similar to that of native LDL. This suggested that GLC-LDL should be a good tracer of LDL receptorindependent catabolism, and if combined with a tracer of total LDL catabolism, should enable one to calculate the extent of LDL receptor-dependent catabolism.
INTRODUCTION
Because low density lipoproteins (LDL) play a central role in the development of atherosclerosis, a detailed understanding of their catabolism is of particular importance. Clearance of LDL from plasma is mediated via a high affinity LDL receptor-dependent pathway as well as one or more LDL receptor-independent pathways (1-3). The receptor-mediated process involves the recognition of apolipoprotein (apo)'-B, the major protein of the LDL particle, by a high affinity receptor present on cell membranes in various tissues, including liver (1) (2) (3) (4) . The classic work of Goldstein and Brown (1) has shown that receptor-mediated endocytosis of LDL leads to an orderly series of biochemical events, which serve to maintain cellular cholesterol homeostasis. In the absence of LDL receptors, as in homozygous familial hypercholesterolemia (HFH) (1) and in the Watanabe heritable hyperlipidemic rabbit (3) (4) (5) , fractional catabolic rates (FCR) of LDL are markedly decreased, plasma LDL levels are grossly elevated, and LDL apo-B production rates are increased (3) (4) (5) (6) (7) . The increased synthesis and degradation of LDL apo-B, of necessity, occurs almost entirely via LDL receptor-independent pathways. It is precisely in this setting of a high LDL flux via nonreceptor pathways that severe and premature atherosclerosis is observed. Thus, it would be important to know the relative contribution to total LDL catabolism of the receptor-independent pathway in man.
We have previously demonstrated that incubation of LDL in the presence of glucose and cyanoborohydride results in irreversible glucosylation of lysine groups of LDL and permanently blocks the ability of LDL to interact with the LDL receptor of fibroblasts (8) . We have also shown that the metabolism of glucosylated (GLC) LDL by mouse peritoneal macrophages that express very few high affinity receptors for native human LDL, is similar to that of native LDL (8, 9) . This suggested that GLC-LDL might be useful for quantitating receptor-independent LDL catabolism in vivo. By combining such a measurement with simultaneous measurement of native LDL catabolism, receptor-dependent and receptor-independent, it is possible to calculate that portion of LDL catabolism accounted for by the LDL receptor pathway (10, 11) . This report describes our initial results using this technique in normoglycemic human subjects.
METHODS
Subjects. All studies reported here were performed on subjects admitted to the Special Diagnostic and Treatment Unit (Metabolic Unit) of the Veterans Administration Medical Center, San Diego, CA. The clinical characteristics of the six individuals studied are presented in Table I . Two of the subjects had suffered myocardial infarction (No. 4 and 5) and one (No. 6) had undergone endarterectomy for carotid vascular disease. Routine clinical laboratory tests indicated that at time of study all were free of thyroid, hepatic, or renal dysfunction, and had normal fasting and 2-h postprandial glucose values. Table I also shows the plasma lipid  and lipoprotein values for each of the subjects, based on  multiple measurements while on a defined diet as described below. Subjects 1, 2, and 3 had normal plasma lipids, while the other three had mild hypertriglyceridemia consistent with phenotype IV. None of the subjects had followed a therapeutic diet or received hypolipidemic drug therapy for the 3 mo before the study period. Subjects 1 and 2 participated in the control turnover studies and subjects [3] [4] [5] [6] participated in the GLC-LDL turnover studies. All patients gave informed consent for the investigations, which were approved by the Human Studies Committee of the University of California, San Diego.
The subjects were fed an isocaloric, weight-maintenance diet of mixed solid food and liquid formula (Hospital Diet Products, Organon Inc., Buena Park, CA). The diet contained 45% of calories as carbohydrate, 15% as protein, and 40% as fat with a polyunsaturated/saturated fat ratio of 0.2. Cholesterol intake averaged 100-150 mg/d. A detailed description of this diet has been previously published (12) (13) . Three liquid meals and one solid meal were given per day with appropriate vitamins and mineral supplementation. Each subject was weighed daily, and caloric intake adjusted to maintain constant body weight throughout the study period.
Preparation and iodination of LDL. After the subjects had been on the mixed solid food and liquid formula diet for 1-2 wk, plasmapheresis was carried out by collecting blood (500 ml) in sterile, pyrogen-free plastic bags containing 500 mg of the disodium salt of EDTA. Plasma was separated by centrifugation (40C) at 5,500 g for 5 min, and cells were reinfused. Isolation of LDL (d = 1.025-1.060 g/ml) was carried out according to the method of Lindgren et al. (14) , by using sterile techniques as we previously described (13) . Plasma was adjusted to d = 1.025 g/ml with a NaClNaBr solution and centrifuged in a 60 Ti rotor in an L2-65B preparative ultracentrifuge (Beckman Instruments, Inc., Palo Alto, CA) at 59,000 rpm (15'C) for 18 h. The infranate was adjusted to d = 1.060 g/ml and subjected to further ultracentrifugation for 14 h in a 65 Ti rotor at 64,000 rpm (15'C). A final ultracentrifugation was done in a 40.3 Ti rotor at 39,000 for 24 h (15'C), after addition of an equal volume of a NaCl-NaBr solution of d = 1.070 g/ml. The concentrated LDL was then dialyzed against 0.15 M NaCl containing 0.01% EDTA, pH 7.4, (EDTA-saline). The LDL was divided into two equal portions and one was labeled with t25I and the other with t3II by the iodine monochloride (15) . Reactants were added so that the molar ratio of iodine to protein was <1. Free radioiodide was removed by extensive dialysis of the iodinated lipoprotein against EDTA-saline. The amount of free iodide after dialysis was determined by thin-layer chromatography as previously described (13) and averaged 0.08% of total radioactivity for control (C) LDL and 0.05% for GLC-LDL. Specific activities of the labeled LDL preparations ranged between 7.0 and 50 cpm/ng. The degree of lipid labeling was determined in each iodinated lipoprotin as previously described (13) experiments and in vivo turnover studies described below. Preparation of labeled LDL for injection. After removal of glucose and cyanoborohydride by dialysis, the labeled LDL preparations were subjected to centrifugation at 20,000 g for 30 min (40C), the supernatant was then removed and passed through a 0.22-Mm Millipore filter. Sterile human serum albumin in a 5% solution was added to the labeled LDL to dilute the original preparation 10-fold (13) . This solution was then passed again through a 0.22-Mm Millipore filter and aliquots set aside for bacterial and fungal culture and for pyrogen testing.
Study protocol and sample analysis. 12 d after plasmapheresis, -2-8 mg of '"I-GLC-LDL and "3'I-C-LDL protein (total dose 10-50 MCi) was injected intravenously. (In subject 6, the isotope assignment was reversed to demonstrate that the differences in decay were not due to isotopic effect). 10-ml blood samples were collected at 5, 10, 15, 20, 30, and 60 min, and 3, 6, 9, 12, 24, 36, and 48 h; and daily thereafter for 14 d in all subjects and for up to 21 and 48 d in two subjects. Determinations of total plasma radioactivity and total cholesterol and triglyceride concentrations were made on each sample. Lipoprotein quantitation was done biweekly during the study period on plasma obtained after a 12-h fast. Urine specimens were collected in bottles containing an alkaline preservative (16) and were pooled during the following time intervals after the intravenous injection of labels: "0 time" to 1, 1-3, 3-6, 6-12, and 12-24 h and for every 24-h period thereafter. Values for urinary radioactivity were normalized to a constant creatinine excretion. All radioactivity was determined in a double channel model 5820 automatic gamma spectrometer (Packard Instrument Co., Downers Grove, IL). Plasma lipids and lipoproteins were determined as described in the Lipid Research Clinic Manual of Laboratory Operations (17) with a Technicon AutoAnalyzer Model II (Technicon Instruments Corp., Tarrytown, NY).
Stability of labeled lipoproteins in vivo. To demonstrate that the physical properties of the labels in plasma did not change after injection, we did the following experiments with plasma obtained 15 min, and 1, 4, 7, and 11 d after injection. Because whole plasma radioactivity was determined, it was important to document that the radiolabel remained protein-bound. Therefore, an aliquot of each sample was precipitated with 10% trichloroacetic acid (TCA); for all samples, 90±2% of 1251 counts (GLC-LDL) and 89±6% of '"'I counts (C-LDL) were TCA-insoluble. Plasma samples were also subjected to ultracentrifugation, and the 1.020-1.070 density range isolated; 91±6% of "2I counts (GLC-LDL) and 88±10% of 13"1 counts (C-LDL) were recoverable in the LDL density range. As previously reported, GLC-LDL has enhanced mobility when subjected to electrophoresis in agarose (8) . To further document the in vivo stability of GLC-LDL, agarose gel electrophoresis was performed on plasma samples obtained up to 8 d after injection of 1251_ GLC-LDL and I3I1-C-LDL. In every case, all 125I plasma radioactivity retained electrophoretic mobility equal to that of the starting GLC-LDL preparation, and always greater than that of C-LDL. In summary, these studies suggest that nearly all plasma radioactivity remained associated with C-LDL and GLC-LDL, respectively, during the course of the turnover studies and that glucosylation of LDL was not reversed.
Data analysis of turnover studies. The kinetic parameters for GLC-LDL and C-LDL turnover were calculated from the plasma decay curves by using curve-peeling methods originally described by Matthews (18) and later adapted to LDL turnover studies by Langer et al. (19) . Plasma volume was calculated by dividing the injected dose of radioactivity by the extrapolated y-intercept of the plasma radioactivity curve. Independent measures of FCR were made by relating the daily urinary excretion rate of '25I and 131I radioactivity to the 1251 and '"'I radioactivity in plasma (U/P ratio) (16) . U/P ratios were calculated as previously described (13) 
RESULTS
Cell culture studies. We have previously shown that with conditions used in these incubations, 45-60% of lysine residues of LDL are irreversibly glucosylated (8, 9) . We, (8) and others (22) have shown that when more than one-third of lysine residues of LDL are blocked, LDL is no longer recognized by the LDL receptor. To document the effectiveness of glucosylation, the degradation of each GLC-LDL preparation was tested on normal human fibroblasts and compared with that of the corresponding C-LDL; in every case, saturable, high affinity degradation was completely blocked for GLC-LDL, but was normal for C-LDL. Fig. 1 (left panel) shows the degradation of C-LDL and GLC-LDL vs. LDL concentration for the labeled preparations of subject 6; virtually identical results were found for each of the other subjects.
The results with the "special control" preparations indicated that in fibroblasts the degradation of LDL was unaffected by cyanoborohydride treatment or incubation at 370C in the absence of glucose. Fig. 1  (right panel) (Fig. 2A) . To rule out any effect of the 5-d incubation at 37°C on the catabolism of C-LDL, an iodinated LDL preparation kept at 4°C (LDL-4°C, no borohydride) and C-LDL were injected simultaneously into subject 2. The FCR for the LDL-4°C was 0.57 d-' and for the C-LDL, 0.52 d-1 (Fig. 2B) Catabolism of GLC-LDL and C-LDL. The catabolism of GLC-LDL was remarkably slower than that of C-LDL in each of the four subjects studied as shown in Fig. 3 . The kinetic parameters for GLC-LDL and C-LDL turnover are shown in Table II . The FCR of C-LDL ranged from 0.345 to 0.724 d-', while that for GLC-LDL ranged from 0.071 to 0.141 d-' (mean 0.11±0 03). However, in all four subjects, the FCR of GLC-LDL as a percentage of that for C-LDL was remarkably constant, 19.5-20.6%. When the U/P ratio data were used to calculate the FCR of each tracer, GLC-LDL again accounted for only 20% or less of total LDL catabolism (Table II) . The FCR for C-LDL derived from the U/P ratios, however, must be qualified by the observation that the U/P ratios were not constant over time, but showed an initial rise and subsequent slow decline with time (Fig. 4) . Others (23, 24) have described a similar finding for the turnover of native LDL. In contrast, after 2 d, the U/P ratio for GLC-LDL was remarkably constant. Assuming GLG-LDL traces only the clearance of the receptorindependent pathway, it follows that the LDL receptor pathway accounted for 80% of total LDL clearance in each subject. In terms of absolute catabolic rates, receptor-mediated catabolism of LDL protein ranged from 10.5 to 20.5 mg/d per kg among these four subjects, while receptor-independent catabolism ranged from 2.7 to 4.9 mg/d per kg. Assuming that all LDL cholesterol is catabolized as a unit with LDL protein, it can be estimated that receptor-mediated clearance of LDL cholesterol ranged from 14.9 to 20.2 mg/d per kg (Table III) .
In contrast with the two exponentials found in each decay curve of the control LDL, the die-away curve of GLC-LDL was monoexponential in each of the patients even when followed for 48 d after injection. The monoexponential decay was observed even during the first few hours after injection during which numerous separate measurements were made. Fig. 5 shows the decay of GLC-LDL during the first 6 h for subject 3 whose complete decay curve can be seen in Fig. 3C . The slow monoexponential decay was also reflected in the low and constant U/P ratio noted in all subjects. The monoexponential decay of GLC-LDL cannot be explained by a different initial volume of distribution because the calculated plasma volumes were the same for both C-LDL and GLC-LDL tracers (Table II) .
Accelerated catabolism of GLC-LDL in some subjects. Subsequent to the studies above, we had the opportunity to study an individual with hypothyroid- 
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FIGURE 3 Turnover of C-LDL (0) and GLC-LDL (A) in human subjects. For each subject, an equal amount of '25I-GLC-LDL and '3tI-C-LDL was injected simultaneously and plasma decay curves subsequently determined over the following [14] [15] [16] [17] [18] Fraction of intravascular apo-LDL pool metabolized each day was calculated from the plasma die-away curve and from U/P ratio. I Plasma volume calculated separately for C-LDL and GLC-LDL by isotope dilution technique as described in Methods. and '3'I radioactivity (C-LDL [0]) obtained in subject 3 (turnover data given in Fig. 3G ). The U/P ratio was determined as described in Methods. Note the low and rather flat U/P ratio for GLC-LDL consistent with its slow, monoexponential decay from plasma.
biphasic decay pattern. However, after 4 FiGURE 5 Plasma decay curve for GLC-LDL during the first 6 h after injection in subject 3 (Fig. 3C ). Plasma radioactivity is expressed as fraction of dose injected. Plasma decay curves for C-LDL (C) and GLC-LDL (Ax) in a 42-yr-old man with mild hypothyroidism (thy- (8) . In the present study, we extend the prior obser- an adequate tracer for the receptor-independent pathway. The modification is irreversible and total blockade of receptor-mediated degradation of GLC-LDL in fibroblast culture was verified for each injected GLC-LDL of the present study (Fig. 1) . The observations that all plasma radioactivity originally used to label GLC-LDL retained enhanced electrophoretic mobility, the monoexponential decay of GLC-LDL for up to 48 d, and a rather flat U/P ratio all attest to the in vivo stability and persistent homogeneity of the GLC-LDL tracer.
Does glucosylation of LDL cause LDL to be uniquely recognized by any LDL receptor-independent pathway such as those that exist on macrophages? We have previously shown that degradation of GLC-LDL by macrophages is no different than that of native or C-LDL (8) and the current observation that it has a slow monoexponential decay from plasma strengthens the suggestion that GLC-LDL has no enhanced clearance by any reticuloendothelial system. Finally, does glucosylation of LDL inhibit its in vivo clearance by any receptor-independent pathway(s)? Two lines of evidence suggest it does not. First, in the guinea pig, the clearance of GLC-LDL is identical to the clearance of methyl LDL (9) . Second, and of particular relevance, we (9) have also shown that the turnover of GLC-LDL is similar to that of native LDL in the Watanabe heritable hyperlipidemic rabbit, an animal model for HFH, which has <5% of normal LDL receptors (3) (4) (5) . In sum, our data suggest that GLC-LDL is an appropriate tracer for the receptor-independent pathway.
The FCR values for total LDL catabolism in our subjects ranged from 0.345 to 0.724 d-'. In a recent review (26) of 15 separate published reports of LDL turnover in normal subjects, we calculated a mean FCR of 0.371 d-', which is similar to the value of 0.345 found for normolipidemic subject 3. The FCR for subjects 4-6 were much higher, possibly reflecting their obesity and/or associated hypertriglyceridemia. We (27) and others (28) have reported that such subjects have LDL FCR values that range between 0.504 and 0.768 d-'. Despite the wide range of total LDL catabolism noted in the subjects of this report, it is remarkable that LDL receptor-dependent catabolism accounted for -80% of total LDL catabolism in each subject. This was true whether the receptor-dependent contribution was determined from the difference in the plasma die-away curves or as calculated from the U/P ratio data. These data are in agreement with the predictions of Goldstein and Brown (1) (8, 9) . Using GLC-LDL in the rabbit, we found that 75% of catabolism was receptormediated (9) , which agrees with the value of 67% found by Bilheimer et al. (29) (30) (31) (32) . The similarity in values of FCR for GLC-LDL in our subjects and for native LDL in HFH subjects strongly supports the view that GLC-LDL traces all of the receptor-independent pathways of LDL catabolism and only those pathways. In contrast, the FCR in normal subjects of cyclohexanedione (CHD)-modified LDL, which has also been used as a tracer of the receptor-independent pathway, has ranged from 0.163 to 0.261 d-' (11, (25) (26) (27) (28) (29) (30) (31) (32) (33) , values higher than those for native LDL in HFH subjects. This suggests that CHD-LDL overestimates the receptor-independent pathway. In fact, using CHD-LDL, Shepherd et al. (11) and Thompson et al. (32) estimated that in man LDL receptor-dependent catabolism accounted for only 33-40% of total LDL catabolism. We found in the guinea pig that turnover of CHD-LDL is consistently greater than that of either GLC-LDL or methyl LDL (which are equal) (9) and Slater et al. (34) have reported that CHD-LDL is cleared more rapidly than methyl LDL in the rabbit (34) . The reasons for the more rapid clearance of CHD-LDL are not clear but could be due to enhanced clearance of CHD-LDL by a nonreceptor mechanism (34), or to slow spontaneous reversal of the CHD modification, as first demonstrated by Mahley et al. (10) and confirmed by Slater et al. (34) and by us (9) .
The decay curve for native LDL has an initial rapid phase of decay that lasts for 2-5 d, followed by a second, slower phase. The U/P data also suggest heterogeneity in the metabolism of LDL. In sharp contrast, the decay of GLC-LDL was monoexponential even when followed for as long as 48 d. The exact explanation for this is unknown, but to our knowledge the only physiologic difference between the two tracers is the inability of GLC-LDL to interact with the LDL receptor. This suggests that the biphasic curve for na-tive LDL clearance is caused by reversible binding to readily accessible LDL receptors (as in liver, spleen, or endothelial cells) or that reversible exchange with an extravascular compartment occurs chiefly by an LDL receptor-dependent process.
Originally, we planned to study a larger number of subjects with this technique. However, in three of four diabetic patients, one hypothyroid subject, and one other normal control after several days of monoexponential decay, we noticed the abrupt onset of a phase of rapid clearance of GLC-LDL that began 4-10 d after injection. We are currently investigating this phenomenon and preliminary evidence suggests that it may be immunological in origin. In guinea pigs, nonenzymatic glucosylation of homologous LDL renders it immunogenic (35) . Furthermore, in two of the human subjects, in whom the rapid decay was seen, (including the subject of Fig. 6 ) preliminary evidence suggests that antibodies against GLC-LDL, but not C-LDL, were present in plasma obtained before injection of the tracers. However, in none of the subjects of the present report have such antibodies been found. Although we have noticed no adverse effects in any of our patients, we would urge caution in further in vivo studies with GLC-LDL until a better understanding of this phenomenon has been achieved.
